Key Takeaway: Sanofi has provided an official update concerning the total number of voting rights and shares as of August 31, 2023. The report states that the total number of issued shares is 1,264,525,904, with 1,412,690,364 real voting rights and 1,423,592,603 theoretical voting rights, including treasury shares. This information is disclosed in compliance with French regulations and is available on Sanofi's investor relations website.
Price reaction · baseline $53.59 (2023-09-08 close) · 1 other SNY headline(s) in the window, move may be shared
day 0 close · peak
+1.6%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+11%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
teplizumab/mL
Phase 2 · Diabetes Mellitus, Type 1
Full Press Release Details
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
a French société anonyme with a registered share capital of 2,529,036,828 €
Registered office : 46, avenue de la Grande Armée - 75017 Paris - France
Registered at the Paris Commercial and Companies Registry under number 395 030 844
Date
Total number of issued shares
Number of real voting rights (excluding treasury shares)
Theoretical number of voting rights (including treasury shares)*
August 31, 2023
1,264,525,904
1,412,690,364
1,423,592,603
* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.
This information is also available on the internet website of sanofi under « Regulated Information in France »: